GromovaMVaggelasADallmannGSeimetzD. Biomarkers: opportunities and challenges for drug development in the current regulatory landscape. Biomark Insights. 2020;15:1177271920974652. doi:10.1177/1177271920974652
2.
DiMasiJAGrabowskiHGHansenRW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33. doi:10.1016/j.jhealeco.2016.01.012
3.
WagnerJA. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol. 2008;48:631-651. doi:10.1146/annurev.pharmtox.48.113006.094611
4.
Carrasco-ZaniniJPietznerMDavitteJ, et al.Proteomic signatures improve risk prediction for common and rare diseases. Nat Med. 2024;30:2489-2498. doi:10.1038/s41591-024-03142-z
5.
ParraERVillarroel-EspindolaFBehrensC, et al.Multi-omics analysis reveals immune features associated with immunotherapy benefit in patients with squamous cell lung cancer from Phase III Lung-MAP S1400I trial. Clin Cancer Res. 2024;30(8):1655-1668. doi:10.1158/1078-0432.CCR-23-0251
6.
ZannadFFerreiraJPPocockSJ, et al.Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme. Eur Heart J. 2022;43(48):4991-5002. doi:10.1093/eurheartj/ehac495
